Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Soft Tissue Sarcoma Drug Gets FDA Accelerated Approval

XTALKS VITALS NEWS

Chemotherapy

The drug has been approved to be used in combination with the chemotherapy drug, doxorubicin, in treating patients with soft tissue sarcoma who cannot be cured with surgery, radiation or anthracycline chemotherapy.

Tweetables from this article:

Tweet: Soft tissue sarcomas are cancers which develop in soft tissue such as muscle, fat or tendons http://ctt.ec/l6PfI+ Soft tissue sarcomas are cancers which develop in soft tissue such as muscle, fat or tendons.

Share this!

October 21, 2016 | by Sarah Hand, M.Sc.

Eli Lilly’s Lartruvo (olaratumab) has received accelerated approval from the US Food and Drug Administration (FDA), for the treatment of select types of soft tissue sarcoma. The drug has been approved to be used in combination with the chemotherapy drug, doxorubicin, in treating patients with soft tissue sarcoma who cannot be cured with surgery, radiation or anthracycline chemotherapy.

Soft tissue sarcomas are cancers which develop in soft tissue such as muscle, fat or tendons. According to the National Cancer Institute, 12,310 cases of the cancer are diagnosed each year, with 5,000 patients likely to die of the disease in 2016.

Soft tissue sarcoma is commonly treated with doxorubicin as a monotherapy or in combination with other drugs, if the tumor cannot be removed surgically. But some patients’ tumor types have been unresponsive to conventional treatment, leaving them with few options.

“For these patients, Lartruvo, added to doxorubicin, provides a new treatment option,” said Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and acting director of the FDA's Oncology Center of Excellence. “This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin's approval more than 40 years ago.”



As a platelet-derived growth factor (PDGF) receptor-alpha blocking antibody, Lartruvo prevents these receptors from becoming stimulated, which may stop tumor growth. In a randomized clinical trial involving 133 patients with different subtypes of metastatic soft tissue sarcoma, Lartruvo was assessed for both safety and efficacy.

Patients were given Lartruvo in combination with doxorubicin, or doxorubicin as a monotherapy. The median survival for patients in the Lartruvo treatment group was 26.5 months, compared to 14.7 months in the doxorubicin arm.

In addition, progression-free survival for Lartruvo patients was nearly doubled, to 4.2 months, compared to 4.4 months for patients taking doxorubicin alone. Finally, patients on the Lartruvo-doxorubicin combo saw significant tumor shrinkage of 18.2 percent, compared to 7.5 percent for doxorubicin patients.

In addition to receiving accelerated approval, the FDA granted Eli Lilly fast track designation, breakthrough therapy, priority review status and orphan drug designation for Lartruvo. Eli Lilly is currently conducting a larger clinical trial to assess the drug’s efficacy across more subtypes of soft tissue carcinoma.


Keywords: Cancer, FDA, Chemotherapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.